Strontium ranelate v placebo for postmenopausal women with osteoporosis*
| Outcomes at 3 years | Strontium | Placebo | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | ||||
| New vertebral fracture | 21% | 33% | 36% (24 to 47) | 9 (7 to 14) |
| Vertebral height loss ⩾1 cm | 30% | 37.5% | 20% (7 to 31) | 14 (9 to 40) |
| Non-vertebral fracture | 16% | 17% | 8% (−17 to 27) | Not significant |